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ABSTRACT
Introduction As new topical and systemic treatments 
become available for atopic dermatitis (AD), there is a need 
to understand how treatments are being used in routine 
clinical practice, their comparative effectiveness and their 
long- term safety in diverse clinical settings.
Methods and analysis The TARGET- DERM AD cohort is a 
longitudinal, observational study of patients with AD of all 
ages, designed to provide practical information on long- 
term effectiveness and safety unobtainable in traditional 
registration trials. Patients with physician- diagnosed AD 
receiving prescription treatment (topical or systemic) 
will be enrolled at academic and community clinical 
centres. Up to 3 years of retrospective medical records, 
5 years of prospective medical records, and optional 
biological samples and patient- reported outcomes will be 
collected. The primary aims include characterisation of AD 
treatment regimens, evaluation of response to therapy, and 
description of adverse events.
Ethics and dissemination TARGET- DERM has been 
approved by a central IRB (Copernicus Group IRB, 5000 
Centregreen Way Suite 200, Cary, North Carolina 27513) 
as well as local and institutional IRBs. No additional 
Ethics Committee reviews. Results will be reviewed by a 
publications committee and submitted to peer- reviewed 
journals.
Trial registration number NCT03661866, pre- results.
BACKGROUND
Atopic dermatitis is, by definition, a chronic 
condition that waxes and wanes over time.1 
Defects of the epidermal barrier, immune 
dysregulation and environmental factors are 
thought to affect disease expression, and it is 
now recognised as a lifelong disposition with 
variable clinical manifestations.2 3 Despite 
being one of the leading contributors to 
non- fatal disease burden worldwide, very 
little is understood about long- term disease 
control.4 5
Pragmatic, real- world studies that capture 
long- term variability in atopic dermatitis disease 
activity and management are needed and can 
provide complementary data to clinical trials. 
Based on growing knowledge of immune path-
ways, the pharmacological options for manage-
ment of atopic dermatitis have expanded over 
the past several years, with further expansion 
expected during the next decade.6 Clinical 
trials are often performed in highly selected, 
adherent study participants who lack signif-
icant comorbidities beyond the disease in 
question. These trials are a good measure of 
clinical efficacy, but the more germane ques-
tion for clinicians and their patients is one of 
real- world effectiveness. Indeed, participants 
enrolled in dermatology clinical trials may not 
be highly representative of the general atopic 
dermatitis population.7–9 Subgroups that might 
be excluded or under- represented in clinical 
Strengths and limitations of this study
 ► TARGET- DERM atopic dermatitis is a longitudinal 
cohort study of patients with atopic dermatitis, in-
cluding up to 3 years of retrospective data and 5 
years of prospective data, allowing for assessment 
of changes over time in individual patients.
 ► The study has broad inclusion criteria to allow for 
capture of patient populations that may be under- 
represented in clinical trials, and inclusion of pa-
tients from both academic and community practices 
will improve generalisability.
 ► The study relies on standardised extraction from 
routinely collected medical records.
 ► The study collects validated investigator global as-
sessments and quarterly patient- reported outcome 
measures.
 ► The study has a biospecimen collection.
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trials include racial/ethnic minority and socioeconomic 
groups, paediatric and geriatric populations, individuals 
with multiple comorbidities and pregnant women. Addi-
tionally, since most trials make comparisons between active 
ingredients and placebos, more data from direct compar-
isons between therapies (both new and conventional) are 
needed.10
The overarching objective of the TARGET- DERM AD 
cohort is to understand the comparative effectiveness 
and long- term safety of atopic dermatitis treatments. The 
cohort will also serve as a core resource to understand real- 
world treatment patterns and disease comorbidities, and 
to perform translational studies using longitudinal clinical 
data linked to patient- reported outcomes data and biospec-
imens. The ultimate goal is to improve patient care for AD. 
TARGET- DERM is a cooperative consortium of principal 
investigators from academic institutions and community 
sites. It is based on a successful model from prior TARGET 
studies used to elucidate the natural history of disease 
and comparative effectiveness for several gastrointestinal 
diseases, starting with hepatitis C.11
METHODS AND ANALYSIS
Study design
TARGET- DERM AD is a longitudinal, observational 
cohort study of atopic dermatitis. The primary aims of 
TARGET- DERM include characterisation of treatment 
regimens, evaluation of patient outcomes and descrip-
tion of adverse events. Secondary aims include evalua-
tion of the relationship between atopic dermatitis and 
comorbid medical conditions. No specific treatments will 
be dictated by enrolment into the study; patient manage-
ment will follow each site’s local standard of care.
Adult and paediatric patients of all ages will be enrolled 
from up to 100 practices, including both academic 
practices affiliated with a university health system and 
community- based or private practice clinical centres. The 
first patient was enrolled on 25 January 2019 and, as of 
March 2020, there are 34 active sites and an additional 
10 in the start- up phase (figure 1). Site recruitment is 
ongoing. Enrolment rates by site type, geography, patient 
age, patient race/ethnicity, socioeconomic status and 
type of treatment (topical vs systemic) are reviewed by the 
academic steering committee monthly and compared with 
national statistics. The recruitment strategy is designed to 
be adaptive to ensure adequate cohort diversity.
Study participants
As this study seeks to reflect real- world clinical practice, 
there are minimal inclusion/exclusion criteria. Patients 
of all ages being managed or treated for atopic derma-
titis with at least one prescription treatment will be 
enrolled. A diagnosis of atopic dermatitis made by the 
treating physician, as in standard clinical practice, will 
be required for enrolment. During site orientation, diag-
nostic recommendations from the American Academy of 
Dermatology will be reviewed with enrolling physicians, 
and participants will be asked UK Working Party criteria 
at enrolment to enable post- hoc evaluations based on 
these diagnostic criteria.12 13 Patients will be excluded if 
they are unable to provide written informed consent or 
assent, or are participating in an investigational study of 
a systemic treatment for atopic dermatitis at the time of 
enrolment. Concurrent participation in investigational 
studies of topical treatments or other registries or obser-
vational studies on atopic dermatitis treatment outcomes, 
however, are permitted.
Patient and public involvement
At the time of consent, patients in TARGET- DERM are 
presented with joining this study as a way to advance 
research in their disease area. In addition, a non- profit 
medical specialty society dedicated to education and 
research on atopic dermatitis, the International Eczema 
Council, has joined the steering committee. Patients were 
not directly involved with the development or conduct of 
the study. The plan is to share study results through publi-
cation; posters and manuscripts will be displayed on the 
TARGET website.
Study procedures
After informed consent is obtained and eligibility 
confirmed, baseline demographic and background infor-
mation will be collected. On enrolment and during each 
follow- up visit for atopic dermatitis, clinicians will record 
a validated investigator global assessment (vIGA- AD) 
score.14 Up to 3 years of retrospective medical records, 
and up to 5 years of prospective medical records will be 
collected biannually. Records will include clinic notes, 
hospitalisations, laboratory reports, telephone contact 
reports, medication lists, biopsy results and imaging. 
Structured variables to be extracted from these records 
include demographic factors, personal and family 
medical history, AD disease characteristics, current 
medications, laboratory tests and detailed AD treatment 
history (box 1). There are no study- mandated interven-
tions planned.
Participants will be asked to complete patient- reported 
outcome (PRO) assessments at baseline and every 
Figure 1 TARGET- DERM has active community (24) and 
academic (10) sites across the USA.
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3 months thereafter. These address itch, pain and sleep, 
quality of life, severity, work productivity and activity 
impairment, tailored to adult or paediatric populations 
(table 1). PROs were chosen based on Harmonizing 
Outcome Measures in Eczema clinical practice set recom-
mendations,15 and core domains for participants on 
systemic and phototherapies will include those recom-
mended by the international treatment of atopic derma-
titis registry task force (TREAT) eDelphi exercise.16
Optional biological samples will be collected yearly for 
future translational research on genetic and immmuno-
phenotypes and include blood, cutaneous tape strips and 
saliva. Participants will consent to each optional specimen 
separately. When possible, blood samples will be collected 
during regular clinical blood work.
The TARGET steering committee (currently composed 
of the academic coauthors on this manuscript) developed 
the study protocol and research plan and gave input on 
site selection and database design. The study is privately 
funded by TARGET PharmaSolutions and can be used 
to provide postauthorisation safety data as requested by 
licensing and regulatory bodies. TARGET stakeholders, 
including steering committee members, industry part-
ners, regulatory representatives, and a nonprofit medical 
specialty society participate in steering committee meet-
ings to drive the research agenda for TARGET studies. 
The steering committee has oversight over any public 
dissemination of the data generated in this study.
Data management
Participating investigational sites provide medical records 
(including structured and unstructured data) from 
consented participants. All data will be processed and stored 
centrally via an electronic data capture system maintained 
by TARGET PharmaSolutions. Biosamples will be collected 
at the sites, sent for storage at a central biorepository and 
tracked in the electronic data capture system by TARGET; 
investigators and stakeholders can apply to use the samples 
for future research. Coding of data will be performed using 
standardised data extraction forms and MedDRA17 and 
WHODrug18 dictionaries. Data will be monitored for quality 
and missingness. Specific efforts will be made to investigate 
and document any reasons leading to premature study 
termination. Adverse events will be evaluated bi- annually 
and reported to regulatory bodies as outlined in the study 
safety monitoring plan.
Study outcomes
The primary study outcomes are response to therapy 
and adverse events. Response to therapy will be based on 
changes in vIGA- AD as collected during standard care 
visits and change in patient- reported outcomes collected 
quarterly. Changes in therapy (ie, discontinuation, step-
ping- up, or stepping down) will also be considered. 
Adverse events will be defined as any untoward medical 
occurrence which deviates from, or is an exacerbation 
of, the subject’s medical history after the time of consent. 
Additional secondary outcomes include the occurrence 
and impact of comorbid medical conditions on treatment 
regimens and vice versa.
Sample size
At least 4000 study participants from up to 100 clinical 
centres will be recruited for TARGET- DERM- AD. The 
sample size was chosen based on logistical consider-
ations and the ability to address multiple study objectives; 
post- hoc calculations suggest that a sample size of 4000 
AD participants (assuming 2000 per group) would enable 
detection of effect sizes as small as 0.07 for changes in the 
primary outcome of vIGA- AD.
DISCUSSION
TARGET- DERM AD is designed to enable the study of 
real- world treatment patterns and long- term outcomes 
in atopic dermatitis, including both comparative effec-
tiveness and safety endpoints. The study has broad 
inclusion criteria to allow for capture of patient popu-
lations that may be underrepresented in clinical trials, 
Box 1 Categories for structured clinical record data 
extraction
 ► Demographic information: sex at birth, age, race/ethnic group, em-
ployment status, country of origin, insurance type.
 ► Atopic dermatitis (AD) characteristics: age of onset, standardised 
vIGA- AD score*, total body surface area affected.
 ► Additional medical history: medical diagnoses (historical and new), 
pregnancies (with due date and pregnancy outcome), number/
relation of relatives with history of AD, number/relation of family 
with history of allergic diseases (allergic rhinitis, asthma, hay fe-
ver), personal history of other immune- mediated inflammatory skin 
conditions,
 ► Substance use: alcohol, tobacco, vaping use and frequency, mari-
juana use, other recreational drug history.
 ► Current medications: concomitant medications with reasons for 
medications.
 ► Clinical/laboratory measures: height, weight, white blood cell, 
neutrophils, lymphocytes, haemoglobin, platelet count, serum 
alanine aminotransferase, aspartate transaminase, gamma- 
glutamyltransferase, total bilirubin, direct bilirubin, indirect bilirubin, 
albumin, creatinine, glucose, calcium, magnesium, phosphorus, 
potassium, sodium, urea nitrogen, creatine kinase, low- density li-
poprotein, high- density lipoprotein, triglycerides, total cholesterol, 
other labs.
 ► Procedures: allergy testing, skin biopsies (with type, reason for biop-
sy, location and pathology report if available), other procedures with 
indication and date.
 ► AD treatment details: current and prior systemic therapy/medication 
name with start/stop/treatment vehicle, topical therapy/medication 
name with start/stop/treatment vehicle, phototherapy type with 
start/stop, dose changes/interruptions/discontinuations, reason for 
dose changes/interruptions/discontinuations.
 ► AD treatment safety: adverse events, serious adverse events, alter-
native treatments used (type, treatment vehicle, concentration).
*Note that as part of the study protocol, clinicians are asked to perform a 
standardised vIGA- AD at each standard of care visit.
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and recruitment of participants from a diverse group of 
academic and community practices will improve gener-
alisability. TARGET- DERM AD fills an important niche; 
although other atopic dermatitis registries exist, these 
are largely focused on the impacts of specific treat-
ments (Pediatric Eczema Elective Registry (PEER) and A 
Prospective Pediatric Longitudinal Evaluation to Assess 
the Long- Term Safety of Tacrolimus Ointment for hte 
Treatment of Atopic Dermatitis (APPLE)),19 20 skin infec-
tions associated with AD (Atopic Dermatitis Research 
Network),21 or systemic treatments (TREAT).22
An important limitation is documentation of atopic 
dermatitis disease activity, which could be prone to 
inaccuracies when relying on real- world assessments. In 
particular, the frequency of patient visits and details in 
routinely collected medical records may not accurately 
capture intermittent disease activity and severity. Regular 
quarterly patient reported assessments and biosamples 
will enhance the internal validity for the subset of partici-
pants consenting to these additional outcomes.
TARGET- DERM AD will serve as the prototype for a larger 
cohort study of immune- mediated inflammatory skin condi-
tions (IMISC), to ultimately include additional participants 
with psoriasis, hidradenitis suppurativa, vitiligo, and alopecia 
areata, and to enrol up to 15 000 participants. Although 
multiple registries and cohorts for psoriasis exist,23–25 such 
data sources are limited for other inflammatory skin diseases. 
Given the overlap in risk factors and treatment options for 
IMISC, a joint registry will benefit the growing understanding 
of these diseases, including the natural history, heterogeneity 
of different patient subpopulations, real- world management 
strategies and response to treatment. Additionally, ongoing 
monitoring of side effect profiles of emerging therapeutic 
agents used for multiple indications will enhance knowledge 
of the safety profile. Furthermore, the availability of an estab-
lished cohesive research network allows nimble responses 
to investigations of new treatment paradigms with existing 
agents, as well as future generations of IMISC therapies.
ETHICS AND DISSEMINATION
The protocol was approved by a central institutional review 
board (Copernicus IRB), and site- specific IRB approvals 
are obtained prior to patient enrolment where required 
(see online supplemental file 1). Results will be published 
in peer- reviewed journals and presented at national and 
international meetings and reported in accordance with the 
Strengthening the Reporting of Observational Studies in 
Epidemiology recommendations.
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screening/enrolment visit. Additional interim medical records submissions may be requested.
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‡Validated Investigator Global Assessment (vIGA) ±body surface area assessment will be obtained at baseline and all follow- up visits.
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